Cidara Therapeutics, Inc. surges to $217 on a bid by Merck & Co., Inc. valuing shares at $221.50. Learn more about CDTX stock ...
Merck & Co., Inc. acquires Cidara Therapeutics, Inc. for $9.2bn, boosting its pipeline with CD388's strong flu data. Click ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback